Restore Medical Welcomes Chris Cleary as Chairman of the Board
Restore Medical Ltd. is thrilled to announce the appointment of Chris Cleary as its new Chairman of the Board of Directors. This transition comes at an exciting time when the company is poised to advance its clinical pathway towards groundbreaking studies in heart failure treatment.
About Restore Medical's Innovative Approach
Founded to tackle the pressing challenges of heart failure, Restore Medical is dedicated to developing cutting-edge solutions that address the needs of patients. Their proprietary transcatheter therapy is specifically designed to improve cardiac function for those suffering from heart failure with reduced ejection fraction (HFrEF).
Significant Clinical Advancements
With promising results from their early clinical trials, Restore Medical is gearing up for its next phase of clinical development. The appointment of Cleary aims to bolster the leadership and strategic direction of the company as it looks toward broader global horizons and upcoming clinical studies in the United States focused on their innovative therapy.
Chris Cleary's Extensive Experience
Bringing over thirty years of extensive experience in healthcare and medical technology, Chris Cleary has an impressive record of leading corporate strategies and transformative deals. His previous role as Senior Vice President of Corporate Development at Medtronic encompassed managing pivotal acquisitions, including the monumental $50 billion acquisition of Covidien. Cleary's expertise in high-impact transactions will be invaluable as Restore Medical strives for expansion.
Statements from Leadership
Gilad Marom, the CEO of Restore Medical, expressed enthusiasm about Cleary's new role: "Chris has been a driving force behind some of the most significant partnerships in med-tech. His strategic insight and extensive experience will be crucial as we prepare for pivotal studies and global expansion. We are excited to have him on board."
Cleary shared his own excitement, stating, "Joining Restore at such a pivotal moment is thrilling. Our innovative technology addresses a crucial unmet need in heart failure treatment, and I eagerly anticipate supporting the team as we build a robust clinical and commercial foundation."
About Restore Medical
Restore Medical Ltd. is committed to revolutionizing heart failure treatment through its innovative transcatheter therapy. The company's mission is centered around enhancing the quality of life for millions suffering from heart failure by offering a safe, effective, and minimally invasive solution.
Backed by esteemed healthcare investors including Pitango HealthTech and Peregrine Ventures, as well as the European Innovation Council (EIC) Fund, Restore Medical is making strides in the world of medical technology, all from its headquarters in Or-Yehuda, Israel.
Frequently Asked Questions
What position has Chris Cleary been appointed to at Restore Medical?
Chris Cleary has been appointed as the Chairman of the Board of Directors at Restore Medical.
What is the core focus of Restore Medical's developments?
The company focuses on developing a transcatheter therapy aimed at treating patients with heart failure, specifically those with reduced ejection fraction (HFrEF).
What prior experience does Chris Cleary bring to Restore Medical?
Chris Cleary has over 30 years of experience in healthcare, having held significant leadership roles, including Senior Vice President of Corporate Development at Medtronic.
How is Restore Medical preparing for its clinical development?
Restore Medical is strengthening its leadership team and gearing up for pivotal clinical studies that will expand its innovative treatment options.
Where is Restore Medical headquartered?
Restore Medical is headquartered in Or-Yehuda, Israel, and is backed by various major healthcare investors.
